Drug firm Sanofi today said its specialty care global business unit Sanofi Genzyme has launched its multiple sclerosis treatment drug Aubagio in India.
The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment, Sanofi Genzyme said in a statement.
Commenting on the development, Sanofi India MD N Rajaram said, "For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for treatment of multiple sclerosis around the world; and is now bringing Aubagio, our original research product to India."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app